READ MORE AVANDIA LEGAL NEWS
In late February the Senate Finance Committee released a new report detailing its two-year investigation into Avandia. The committee pointed to official GSK reports linking the drug to more than 80,000 heart attacks in July 2007 and an official FDA report from 2008 that recommended that Avandia be taken off the market. It also noted several attempts by GSK to undermine criticisms of the medication.
The $6 billion estimate comes courtesy of global financial services company UBS, which estimated that GSK could lose between $1 billion and $6 billion, though the liability is expected to fall below the midpoint of this range, according to the report.